Clinical, pathologic, and molecular features of amphicrine prostate cancer.
Laura S GrahamMichael C HaffnerErolcan SayarAgnes GawneMichael Thomas SchweizerColin C PritchardIlsa ColemanPeter S NelsonEvan Y YuPublished in: The Prostate (2023)
We show that amphicrine prostate cancer is a unique entity and differs in clinical and molecular features from high-grade neuroendocrine carcinomas of the prostate. Our study highlights the need to recognize AMPC as a unique molecularly defined subgroup of prostate cancer.